Analyst Ratings February 23, 2026

Compass Point Lifts Macerich Price Target to $22, Cites NOI Recovery and Portfolio Restructuring

Analyst maintains Buy as company outlines NOI guidance, debt reduction targets and redevelopment plan

By Marcus Reed MAC
Compass Point Lifts Macerich Price Target to $22, Cites NOI Recovery and Portfolio Restructuring
MAC

Compass Point raised its price target on The Macerich Company (NYSE: MAC) to $22 from $20 while keeping a Buy rating, pointing to management guidance that forecasts $860 million to $900 million in net operating income on a restructured, higher-yielding portfolio. The stock is trading near its 52-week high after a recent weekly gain, and analysts point to leasing momentum, redevelopment activity and asset sales as the drivers of projected NOI and balance-sheet improvement.

Key Points

  • Compass Point raised its price target for The Macerich Company to $22 from $20 and kept a Buy rating, citing management guidance for $860 million to $900 million in NOI.
  • Macerich is targeting a reduction in leverage to a 6.25-6.55 times ratio from 7.8 times reported for Q4 2025, supported by asset sales, stronger leasing and redevelopment.
  • KeyBanc upgraded the stock to Overweight with a $25.00 price target, citing progress on the Path Forward Plan, including a $107 million small-shop opening pipeline with rent commencements through 2028. Sectors impacted include real estate, retail property and financial markets.

Compass Point has increased its 12-month price objective for The Macerich Company (NYSE: MAC) to $22, up from $20, while retaining a Buy recommendation on the retail-focused real estate investment trust. The broker highlighted management's May guidance as the principal rationale for the adjustment.

In that guidance, Macerich projected net operating income (NOI) in the range of $860 million to $900 million for a portfolio that has been reshaped toward higher-producing properties. That estimate is built on several assumptions explicitly outlined by the company, including the sale of additional assets, NOI expansion driven by stronger leasing metrics, and value added through redevelopment projects.

The shares are trading at $20.30, close to a 52-week high of $20.65, after posting a 9.6% increase over the past week. Compass Point noted that current leasing volume is running ahead of earlier expectations and has contributed to higher same-store NOI to date.

Macerich has also signaled a goal of shrinking leverage over time. Management is targeting a debt ratio in the range of 6.25 to 6.55 times, down from the 7.8 times reported for the fourth quarter of 2025. That targeted reduction in leverage is part of the company’s broader plan to strengthen the balance sheet as the portfolio is repositioned.

Management expects the property base to become smaller as non-core assets are sold, but projects that the go-forward portfolio will generate NOI growth averaging 5% per year over the next four years. Compass Point flagged that the catalysts underpinning this outlook will unfold primarily over the next two years, and cautioned that market-moving upside may not materialize until mid-2027. The firm said that outcome could leave shares largely flat for much of 2026 before improving in the second half of that year.

The company has paid a dividend for 33 consecutive years and presently yields 3.35%. Current leasing activity and the planned redevelopment pipeline are central to management’s forecast for NOI and rental income growth going forward.

Separately, KeyBanc upgraded Macerich’s rating to Overweight from Sector Weight and assigned a $25.00 price target. That upgrade was tied to what KeyBanc described as progress on the company’s multi-year Path Forward Plan. The plan includes a $107 million small-shop new opening pipeline, with annual base rent from those openings expected to commence through 2028. KeyBanc indicated that the Path Forward Plan is executing ahead of expectations, which underpins its more bullish stance.

Together, the analyst actions underscore differing degrees of confidence in Macerich’s execution of asset sales, leasing momentum and redevelopment activity. Investors and market participants will be watching whether the company can deliver the anticipated NOI gains and reach its targeted leverage levels within the stated timeframes.

Risks

  • The NOI projection assumes additional asset sales, improved leasing metrics and redevelopment projects - failure to deliver on these assumptions would undermine the outlook. This affects real estate and retail property sectors.
  • Management’s target to lower leverage from 7.8 times to a 6.25-6.55 times ratio is a stated objective - delays or shortfalls in debt reduction could affect balance-sheet stability and investor confidence in REIT and finance markets.
  • Compass Point noted potential timing delays - upside may not occur until mid-2027, which could leave shares largely unchanged through most of 2026. This timing uncertainty may influence investor behavior across equity and REIT sectors.

More from Analyst Ratings

Raymond James Sees Valuation Gap in Legend Biotech After Gilead Buys Competing Developer Feb 23, 2026 TD Cowen Lifts Lamar Advertising Price Target Citing 2026 Growth Catalysts Feb 23, 2026 TD Cowen Cuts Elastic Price Target to $70 Amid Competitive Pressures Feb 23, 2026 TD Cowen Cuts Cogent Communications Target After Data Center Sale Misses; Waves Progress Limited Feb 23, 2026 RBC Capital Starts Coverage of Light & Wonder With Outperform, $190 Target Feb 23, 2026